Aidoc Submits Generative AI Radiology Tool to FDA for Review

What Happened

Aidoc, a medical AI company, has submitted a generative AI-powered device to the U.S. Food and Drug Administration for regulatory review. The system is designed to interpret medical images and produce draft reports for radiologists, marking one of the first attempts by a medtech company to bring a generative AI diagnostic tool through the FDA's formal clearance process.

What the Device Does

The Aidoc system combines image analysis with generative AI to produce written draft reports, which radiologists would then review and finalise. The tool is intended to assist, not replace, radiologists by automating an initial interpretation step in the workflow. Radiology departments in hospitals and imaging centres handle large volumes of scans, and AI-assisted drafting is positioned as a means of reducing turnaround time for reports.

The device falls under the category of AI-enabled software as a medical device, a classification the FDA has been actively developing frameworks to govern. Aidoc's submission places it at the leading edge of a broader industry effort to bring generative AI capabilities into regulated clinical environments.

Regulatory Context

The FDA has cleared hundreds of AI-based medical devices over the past several years, the majority of which perform narrowly defined detection or triage tasks, such as flagging abnormalities in chest X-rays or CT scans. Generative AI devices, which produce free-text outputs rather than binary or numerical results, present a distinct regulatory challenge because their outputs are more open-ended and harder to validate against fixed benchmarks.

The medtech industry has been waiting for the FDA to issue clearer guidance on how it intends to evaluate generative AI tools. Aidoc's submission is described as a move to engage directly with the agency in the absence of finalised guidance, effectively using the review process itself to help shape regulatory expectations.

According to reporting by MedTech Dive, Aidoc is submitting the device through the FDA's existing premarket pathways while the broader regulatory framework for generative AI in medical settings remains under development.

Company Background

Aidoc was founded in 2016 and has previously received FDA clearance for a range of AI-based clinical tools focused on time-sensitive conditions including pulmonary embolism, intracranial hemorrhage, and aortic dissection. The company's earlier cleared products operate primarily as detection and alerting systems, flagging cases for clinician review rather than generating written interpretations.

The company works with hospital systems across the United States and internationally, and its platform is integrated into radiology workflows at a number of large health systems. The move into generative AI report drafting represents an expansion of the company's product scope beyond detection into documentation.

Industry Significance

Several other companies, including large imaging and health IT vendors, are developing generative AI tools for radiology. However, few have formally entered the FDA review process for devices that produce draft diagnostic language. Aidoc's submission places it among the first to seek clearance specifically for the report-drafting function.

U.S. Congressman Morgan Griffith, Chairman of the House Energy and Commerce Subcommittee on Health, stated this week that smart use of AI has the potential to improve American healthcare, comments that reflect growing congressional attention to AI applications in clinical settings.

The lack of established FDA guidance on generative AI outputs remains a central concern for the medtech sector. Companies developing similar tools are watching Aidoc's regulatory engagement closely as a potential indicator of how the agency will approach review criteria, evidence standards, and post-market monitoring requirements for this class of device.

What Happens Next

The FDA's review timeline for Aidoc's submission has not been publicly disclosed, and the agency has not confirmed when it expects to issue formal guidance specifically addressing generative AI-enabled medical devices.